-FirstPost.com With the hype of his Madison Square Garden show overshadowing everything else, Prime Minister Narendra Modi's US visit was dubbed as a great bilateral victory for India. As the popular consensus went, Modi wowed both the Indian Americans and American politicians and even managed to get a joint op-ed article with President Barack Obama in the Washington Post stressing the importance of the partnership between the two countries. Was it really...
More »SEARCH RESULT
DIPP Statement on Bilateral Mechanism for Discussing IPR Issues with USA
-Press Information Bureau/ Ministry of Commerce and Industry The US- India Joint Statement issued by the Prime Minister of India and the President of the United States of America after the bilateral summit had the following reference to IPR issues "Agreeing on the need to foster innovation in a manner that promotes economic growth and job creation the leaders committed to establish an annual high level Intellectual Property (IP) Working Group...
More »Has PM Modi bowed to US pressure on patent laws? -Rema Nagarajan
-The Times of India A paragraph buried in the US-India joint statement, which talks of establishing an annual high-level Intellectual Property (IP) working group as part of the Trade Policy Forum, has made health activists across the world apprehensive that the Modi government might be bending to US pressure to change its patent laws. Several health policy experts and activists have issued statements urging India not to give in to US...
More »IPR policy in the works
-The Telegraph New Delhi: The government plans to come out with a policy on intellectual property rights (IPR) within a few months, with developed nations such as the US and the EU raising concerns over the country's patent rules. "India does not have an IPR policy. This is the first time we are coming out with a policy. IPR policy issues have been hanging fire for quite a long time," commerce and...
More »Friction over drug patents
-The Hindu Differences over intellectual property rights (IPRs) have emerged as a strong undercurrent in India's economic relations with the U.S. The attempt by the influential pharmaceutical lobby to stymie India's efforts to ensure the supply of medicines at affordable rates without violating existing treaty commitments, requires a principled response from New Delhi. At the core of the issue is what Columbia University Professor Arvind Panagariya calls "the hijacking of...
More »